日报更新时间：
周报更新时间：01-23 11:54
今开价：
最高价：
成交量：
昨收价：
最低价：
最新价：
英文名称：TrovaGene
简介：Trovagene, Inc.是一家出于发展阶段的分子诊断公司，专注由专有产权的诊断技术的开发和市场推广，这种技术在各种医学诊所用于患者/疾病的扫描和监视
电话：1-858-9527570
Trovagene公司主要候选药物——PCM-075是Polo-like激酶1选择性三磷酸腺苷竞争性抑制剂。PCM-075正处于急性髓性白血病（AML）的 Ib/II 期临床试验中，并已完成晚期实体瘤的 I 期临床试验。PCM-075也处于多个临床前研究中，与大约10种化疗药物和目标药物结合用于血液和实体肿瘤癌症，包括：Zytiga（醋酸阿比特龙）; Beleodaq（belinostat）; Quizartinib（AC220），一种开发阶段的FLT3抑制剂; 和Velcade（硼替佐米）在AML，转移性去势抵抗性前列腺癌和其他血液和实体肿瘤癌症。Trovagene, Inc.主要服务于制药公司和第三方实验室。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2019-06-30 | Erlander (Mark) | Officer | Buy | 1250 | -- |
| 2019-06-30 | Erlander (Mark) | Officer | Sell | 461 | -- |
| 2019-03-31 | Erlander (Mark) | Officer | Buy | 1250 | -- |
| 2019-03-31 | Erlander (Mark) | Officer | Sell | 459 | -- |
| 2019-01-01 | Erlander (Mark) | Officer | Sell | 698 | -- |
| 2019-01-01 | Erlander (Mark) | Officer | Buy | 1563 | -- |
| 2018-12-31 | Erlander (Mark) | Officer | Sell | 3035 | -- |
| 2018-12-31 | Erlander (Mark) | Officer | Buy | 7500 | -- |
| 2018-09-30 | Erlander (Mark) | Officer | Buy | 7500 | -- |
| 2018-09-30 | Erlander (Mark) | Officer | Sell | 2731 | -- |
| 2018-06-19 | Markin (Rodney S) | Director | Buy | 41200 | 0.85 |
| 2018-06-07 | Brancaccio (John P) | Director | Buy | 10000 | 0.80 |
| 2018-06-07 | Tennant (Stanley) | Director | Buy | 10000 | 0.80 |
| 2018-01-29 | Welch (William J) | Chief Executive Officer | Sell | 62010 | -- |
| 2018-01-29 | Welch (William J) | Chief Executive Officer | Buy | 130000 | -- |
| 2018-01-29 | Erlander (Mark) | Officer | Buy | 90000 | -- |
| 2018-01-29 | Erlander (Mark) | Officer | Sell | 42930 | -- |
| 2018-01-01 | Welch (William J) | Chief Executive Officer | Buy | 50000 | -- |
| 2018-01-01 | Tennant (Stanley) | Director | Buy | 16667 | -- |
| 2018-01-01 | Markin (Rodney S) | Director | Buy | 16667 | -- |
| 2018-01-01 | Erlander (Mark) | Officer | Sell | 9558 | -- |
| 2018-01-01 | Adams (Thomas H. Jr., Ph.D.) | Director | Buy | 16667 | -- |
| 2018-01-01 | Brancaccio (John P) | Director | Buy | 16667 | -- |
| 2018-01-01 | Billings (Paul R) | Director | Buy | 16667 | -- |
| 2018-01-01 | Welch (William J) | Chief Executive Officer | Sell | 25487 | -- |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Northern Trust Investments Inc | 4487 | 0.09% | 11 | 0.25% | 2019-07-31 |
| Fidelity Management & Research Company | 16156 | 0.31% | -- | -- | 2019-07-31 |
| Geode Capital Management, LLC | 16581 | 0.32% | 16581 | -- | 2019-03-31 |
| Vassalluzzo Scott J | 18679 | 0.36% | 18679 | -- | 2019-03-31 |
| Dimensional Fund Advisors LP | 20519 | 0.39% | -- | -- | 2019-07-31 |
| Dimensional Fund Advisors, Inc. | 20519 | 0.39% | 20519 | -- | 2019-03-31 |
| Vanguard Group Inc | 67764 | 1.29% | 9417 | 16.14% | 2019-03-31 |
| Renaissance Technologies Corp | 160221 | 3.05% | 45759 | 39.98% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 245636 | 4.68% | -- | -- | 2019-07-31 |
| BlackRock Inc | 5546 | 0.11% | 5546 | -- | 2019-03-31 |
| Hudson Canyon Investment Counselors LL | 240 | -- | 240 | -- | 2019-03-31 |
| Bank of Montreal | 2600 | 0.05% | 2350 | 940.00% | 2019-03-31 |
| BlackRock Advisors (UK) Ltd | 348 | 0.01% | 1 | 0.29% | 2019-03-31 |
| Barclays PLC | 348 | 0.01% | 1 | 0.29% | 2019-03-31 |
| BlackRock | 527 | 0.01% | -1 | -0.19% | 2019-07-31 |
| BlackRock Asset Management Canada Ltd | 752 | 0.01% | -- | -- | 2019-07-31 |
| CapTrust Financial Advisors | 785 | 0.01% | -- | -- | 2019-03-31 |
| UBS Group AG | 794 | 0.02% | -5825 | -88.00% | 2019-03-31 |
| FNY Investment Advisers, LLC | 2000 | 0.04% | 2000 | -- | 2019-03-31 |
| BMO Harris Bank NA | 2600 | 0.05% | 2350 | 940.00% | 2019-03-31 |
| Wells Fargo & Co | 517 | 0.01% | 258 | 99.61% | 2018-12-31 |
| Mellon Investments Corporation | 436 | 0.01% | 80 | 22.47% | 2019-06-30 |
| Bank of America Corporation | 417 | 0.01% | 417 | -- | 2018-12-31 |
| Morgan Stanley - Brokerage Accounts | 580 | 0.01% | 202 | 53.44% | 2018-12-31 |
| Susquehanna Financial Group, LLLP | 171956 | 3.28% | 122332 | 246.52% | 2018-12-31 |
| Susquehanna International Group, LLP | 171956 | 3.28% | 122332 | 246.52% | 2018-12-31 |
| Dowling & Yahnke Inc | 62267 | 1.19% | -- | -- | 2018-12-31 |
| Northern Trust Investments N A | 26521 | 0.51% | -- | -- | 2018-12-31 |
| Northern Trust Corp | 26521 | 0.11% | -- | -- | 2018-12-31 |
| TWO SIGMA SECURITIES, LLC | 14825 | 0.06% | -1175 | -7.34% | 2018-09-30 |
| Citadel Advisors Llc | 18260 | 0.08% | -5253 | -22.34% | 2018-09-30 |
| Security National Bank | 41200 | 0.17% | -- | -- | 2018-09-30 |
| Sabby Management LLC | 153638 | 0.64% | -596912 | -79.53% | 2018-09-30 |
| Elkhorn Partners Limited Partnership | 89168 | 0.37% | -- | -- | 2018-09-30 |
| Two Sigma Investments LLC | 37190 | 0.15% | 37190 | -- | 2018-09-30 |
| Vanguard | 9243 | 0.04% | -157 | -1.67% | 2018-12-31 |
| BNY Mellon Asset Management North America Corporation | 7610 | 0.03% | 6160 | 424.83% | 2018-11-30 |
| UBS Securities LLC | 14436 | 0.06% | 12603 | 687.56% | 2018-06-30 |
| BlackRock Institutional Trust Company NA | 32147 | 0.14% | -- | -- | 2018-06-30 |
| CVI Holdings LLC | 307445 | 1.34% | 307445 | -- | 2018-06-30 |
| Goldman Sachs Group Inc | 15013 | 0.07% | -345 | -2.25% | 2018-03-31 |
| Raymond James & Associates | 22000 | 0.10% | -1000 | -4.35% | 2018-03-31 |
| BNY Mellon Investment Management | 26395 | 0.11% | -- | -- | 2018-03-31 |
| Bank of New York Mellon Corp | 31953 | 0.14% | -24535 | -43.43% | 2018-03-31 |
| California Public Employees Retrmnt Sys | 77200 | 0.34% | -- | -- | 2018-03-31 |
| Bigger Capital Fund, LP | 1146800 | 6.48% | -81033 | -6.60% | 2018-08-17 |
| Ayrton Capital LLC | 739922 | 1.25% | 739922 | -- | 2018-06-08 |
| Meeder Asset Management Inc | 6610 | 0.04% | 2544 | 62.57% | 2018-08-31 |
| Mellon Capital Management Corporation | 1971 | 0.01% | 1 | 0.05% | 2018-06-30 |
| Guggenheim Funds Investment Advisors LLC | 4531 | 0.02% | -- | -- | 2018-09-14 |
| BMO Asset Management Inc | 1876 | 0.01% | 1876 | -- | 2018-06-30 |
| J.P. Morgan Securities Inc | 68 | -- | -- | -- | 2018-06-30 |
| Morgan Stanley & Co Inc | 292 | -- | 232 | 386.67% | 2018-06-30 |
| Merrill Lynch & Co Inc | 486 | -- | 486 | -- | 2018-06-30 |
| Morgan Stanley Smith Barney LLC | 42 | -- | 42 | -- | 2018-06-30 |
| Wells Fargo Advisors, LLC | 259 | -- | 217 | 516.67% | 2018-06-30 |
| USAA Asset Management Company | 460 | -- | 460 | -- | 2018-06-30 |
| Vanguard Group Inc. | 509 | -- | 1 | 0.20% | 2018-06-30 |
| BlackRock Fund Advisors | 4268 | 0.02% | 85 | 2.03% | 2018-08-23 |
| Intracoastal Capital LLC | 2666666 | -- | 2666666 | -- | 2017-12-15 |
| Heights Capital Management Inc | 2593218 | -- | 2593218 | -- | 2017-12-31 |
| Prospera Financial Services Inc | 127350 | -- | 1000 | 0.79% | 2017-12-31 |
| Messner Smith Theme Value Inv Mgmt Ltd | 23850 | -- | -3075 | -11.42% | 2017-12-31 |
| CAMBRIDGE Invest RESEARCH ADVISORS, INC. | 21400 | -- | -900 | -4.04% | 2017-12-31 |
| Millennium Management LLC | 111354 | 0.21% | -230989 | -67.47% | 2017-12-31 |
| Princeton Capital Management Inc | 17070 | 0.04% | -18000 | -51.33% | 2017-09-30 |
| Virtu Financial LLC | 79050 | 0.21% | 79050 | -- | 2017-09-30 |
| HighTower Advisors, LLC | 25500 | 0.06% | -40100 | -61.13% | 2017-09-30 |
| Goldman, Sachs & Co. | 14902 | 0.04% | -263284 | -94.64% | 2017-09-30 |
| Davidson D A & Co | 159668 | 0.42% | -21000 | -11.62% | 2017-09-30 |
| BARCLAYS BANK PLC, HONG KONG | 25000 | 0.08% | -- | -- | 2017-06-30 |
| Christian Brothers Inv Srvc Inc | 17017 | 0.06% | -- | -- | 2016-09-30 |
| Windsor Financial Group Llc | 62500 | 0.20% | -- | -- | 2017-06-30 |
| Element Capital Management LLC | 131637 | 0.42% | 131637 | -- | 2017-06-30 |
| Sunrise Partners LLC | 82500 | 0.27% | 82500 | -- | 2017-06-30 |
| State Street Corp | 24800 | 0.08% | -410107 | -94.30% | 2017-06-30 |
| Bridger Management Llc | 2460626 | 8.04% | -829961 | -25.22% | 2016-11-11 |
| Morgens, Waterfall, Vintiadis & Co. Inc | 300000 | 0.98% | -- | -- | 2016-09-30 |
| TIAA-CREF Investment Management LLC | 87532 | 0.29% | -51436 | -37.01% | 2016-09-30 |
| BlackRock Advisors LLC | 112917 | 0.37% | -2515 | -2.18% | 2016-09-30 |
| California State Teachers Retirement Sys | 59677 | 0.20% | 600 | 1.02% | 2016-09-30 |
| Blue Planet Investment Mgmnt | 124468 | 0.40% | -- | -- | 2017-01-31 |
| Gabriele Cerrone | 1852438 | 10.00% | 10484799 | 0.10% | 1999-11-30 |
| Bridger Management,LLC | 3150587 | 10.00% | 17832322 | 0.10% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| USAA Extended Market Index Fund | 76 | -- | -- | -- | 2019-06-30 |
| BlackRock Extended Equity Market | 527 | 0.01% | -1 | -0.19% | 2019-06-30 |
| Vanguard Balanced Index Fund | 3233 | 0.06% | -- | -- | 2019-06-30 |
| DFA US Micro Cap Portfolio | 4000 | 0.08% | -- | -- | 2019-05-31 |
| NT Ext Equity Market Index Fund - L | 4018 | 0.08% | -- | -- | 2019-06-30 |
| DFA Tax Managed US Small Cap Portfolio | 7600 | 0.14% | -- | -- | 2019-06-30 |
| DFA US Targeted Value Portfolio | 8919 | 0.17% | -- | -- | 2019-05-31 |
| Vanguard Extended Market Index Fund | 36281 | 0.69% | -- | -- | 2019-06-30 |
| Vanguard Total Stock Market Index Fund | 245636 | 4.68% | -- | -- | 2019-06-30 |
| Fidelity | 345 | 0.01% | -- | -- | 2019-06-30 |
| NT Extended Equity Market Idx Fund - NL | 217 | -- | -- | -- | 2019-06-30 |
| NT US Market Cap Index Fund - Lending | 84 | -- | -- | -- | 2019-06-30 |
| State Street U.S. Extended Market Index | 143 | -- | -- | -- | 2019-07-31 |
| NT Ext Equity Mkt Fd - DC - NL | 155 | -- | 11 | 7.64% | 2019-06-30 |
| iShares Core S&P US Total Market ETF | 188 | -- | -- | -- | 2019-05-30 |
| iShares Core Balanced ETF Portfolio | 188 | -- | -- | -- | 2019-05-30 |
| iShares Core MSCI AllCntry Wld exCan ETF | 188 | -- | -- | -- | 2019-05-30 |
| iShares Core Growth ETF Portfolio | 188 | -- | -- | -- | 2019-05-30 |
| iShares Core S&P Total US Stock Mkt ETF | 188 | -- | -- | -- | 2019-07-30 |
| BNYM Mellon SL Mkt Completion Fd | 99 | -- | -237 | -70.54% | 2019-03-31 |
| NT Ext Equity Mkt Idx Fd - DC - NL | 155 | -- | 11 | 7.64% | 2019-06-30 |
| BNYM Mellon NSL Mkt Completion Fd Instl | 337 | 0.01% | 317 | 1585.00% | 2019-03-31 |
| BNYM Mellon SL Market Completion Fund | 99 | -- | -237 | -70.54% | 2019-03-31 |
| Vanguard US Equity Index Fund | -- | -- | -509 | -100.00% | 2018-12-31 |
| Meeder Spectrum Fund | -- | -- | -6610 | -100.00% | 2018-09-30 |
| Invesco Wilshire Micro-Cap ETF | -- | -- | -772 | -100.00% | 2019-02-22 |
| BNY Mellon Market Completion Fund | 120 | -- | -514 | -81.07% | 2018-12-31 |
| Master Extended Market Index Series | -- | -- | -5524 | -100.00% | 2018-02-28 |
| The Vanguard Total Stock Market Index | 9243 | 0.04% | -157 | -1.67% | 2017-11-30 |
| JHVIT Total Stock Market Index Tr | 1241 | 0.01% | -- | -- | 2017-07-31 |
| USAA Extended Market Index | 460 | -- | -- | -- | 2018-07-31 |
| iShares Core S&P Total US Stock Mkt | 1128 | 0.01% | -- | -- | 2018-09-12 |
| Vanguard Total Stock Mkt Idx | 1176 | 0.01% | -- | -- | 2018-07-31 |
| BNY Mellon EB DL Mkt Completion | 1971 | 0.01% | 1 | 0.05% | 2018-06-30 |
| Vanguard Balanced Index Inv | 2468 | 0.01% | -- | -- | 2018-07-31 |
| Vanguard Extended Market Idx Inv | 192747 | 1.09% | 157638 | 449.00% | 2018-07-31 |
| Meeder Spectrum | 6610 | 0.04% | 2544 | 62.57% | 2018-08-31 |
| Wilshire Micro-Cap ETF | 4531 | 0.02% | -- | -- | 2018-09-14 |
| BlackRock Extended Equity Market K | 3140 | 0.02% | 85 | 2.78% | 2018-06-30 |
| Fidelity Spartan | 2821 | 0.02% | -- | -- | 2018-07-31 |
| SSgA U.S. Total Market Index Fd Class I | 2885 | 0.07% | -188 | -6.12% | 2017-12-31 |
| BNY Mellon Market Completion Fund UC1 | 7610 | 0.16% | 6160 | 424.83% | 2018-03-31 |
| Nuveen Small Cap Index I | 1764 | 0.07% | -- | -- | 2017-03-31 |
| Christian Bros CUIT Small Cap Eqty Idx B | 17017 | 0.06% | -- | -- | 2016-09-30 |
| Vantagepoint Broad Market Index I | 4449 | 0.01% | -- | -- | 2016-09-30 |
| Vantagepoint Mid/Small Company Index I | 3916 | 0.01% | -- | -- | 2016-09-30 |
| Schwab Instl Small Cap Tr Fd-Instl | 81 | -- | 13 | 19.12% | 2016-12-31 |
| iShares Russell 2000 Growth | 202063 | 0.73% | -- | -- | 2017-02-07 |
| iShares Micro-Cap | 69537 | 0.25% | -- | -- | 2017-02-07 |
| Northern Trust Russell 2000 Index Fund - DC - Non-Lending | 71218 | 0.23% | 402 | 0.57% | 2016-12-31 |
| CREF Stock R1 | 60138 | 0.20% | -- | -- | 2016-12-31 |
| AXA 2000 Managed Volatility K | 40269 | 0.13% | -- | -- | 2016-11-30 |
| BlackRock Russell 2000 | 41330 | 0.13% | 2299 | 5.89% | 2016-12-31 |
| The Vanguard Russell 2000 Growth Index | 41222 | 0.13% | -- | -- | 2016-12-31 |
| TIAA-CREF Small-Cap Blend Idx Inst | 37686 | 0.12% | -- | -- | 2016-12-31 |
| Schwab Small Cap Index | 35347 | 0.12% | -- | -- | 2016-12-31 |
| BlackRock Russell 2500 | 30829 | 0.10% | 48 | 0.16% | 2016-12-31 |
| iShares Russell 2000 Value | 22728 | 0.08% | -90 | -0.39% | 2017-02-07 |
| Carnegie Global Healthcare | 328584 | 1.10% | -- | -- | 2015-10-31 |
| Turner Medical Sciences Long/Short | 183630 | 0.60% | -- | -- | 2015-09-30 |
| CREF Stock Account | 182003 | 0.60% | 17000 | 10.30% | 2015-09-30 |
| Fidelity Spartan® Extended Mkt Indx Fd | 105483 | 0.40% | 5294 | 5.30% | 2015-09-30 |
| The Vanguard - Russell 2000 Grwth Idx CF | 50322 | 0.20% | -- | -- | 2015-10-31 |
| AXA 2000 Managed Volatility Portfolio | 40269 | 0.10% | -- | -- | 2015-09-30 |
| BlackRock Russell 2000® Index Non-Lendable Fund | 38746 | 0.10% | 14241 | 58.10% | 2015-09-30 |
| Schwab Small Cap Index Fund® | 35347 | 0.10% | -- | -- | 2015-09-30 |
| Fidelity Spartan® Total Market Idx Fund | 33847 | 0.10% | -- | -- | 2015-09-30 |
| iShares Russell 2000 (AU) | 466375 | 2.10% | -588 | -0.10% | 2015-11-19 |
| Rodney S. Markin | Rodney S. Markin founded LAB-InterLink. Currently, Dr. Markin is Chairman of PerceptiMed, Inc. He is also Chief Operating Officer at the University of Nebraska and on the board of 6 other companies. Dr. Markin previously held the position of Chairman, President & Chief Executive Officer at UNMC Physicians, Chairman for Transgenomic, Inc., Chief Executive Officer at LAB-InterLink and Chief Technology Officer at the University of Nebraska Medical Center. He received an undergraduate degree from Nebraska Wesleyan University, a doctorate from the University of Nebraska Medical Center and a doctorate from The University of Nebraska-Lincoln. |
|---|---|
| John P. Brancaccio | John P. Brancaccio is on the board of Tamir Biotechnology, Inc. and 4 other companies. In his past career Mr. Brancaccio held the position of Chief Operating & Financial Officer for Eline Entertainment Group, Inc., Chief Financial Officer at Orchestra Medical Ventures LLC, Chief Financial Officer, Secretary & Treasurer of Memory Pharmaceuticals Corp. and Chief Financial Officer at Accelerated Technologies, Inc. Mr. Brancaccio received an undergraduate degree from Seton Hall University. |
| Rodney S. Markin | Dr. Karsten Schmidt is Chief Technology Officer at TrovaGene, Inc. and Head-Administration at Zentrum f�0�1�0�4r Foren in der Grafischen Datenverarbeitung eV. Dr. Schmidt was previously employed as Vice President-Business Development by Sequenom, Inc. He received his doctorate degree from the University of Bonn. |
| Thomas H. Adams | Founder of Gen-Probe, Inc. and Genta, Inc., Thomas H. Adams is a businessperson who has been at the helm of 7 different companies and presently holds the position of Chairman & Chief Executive Officer of TrovaGene, Inc. Dr. Adams is also on the board of ContraVir Pharmaceuticals, Inc. and Gensignia Life Sciences, Inc. In his past career Dr. Adams was Executive Chairman of Clearbridge Biophotonics, Inc., Chief Executive Officer for Genta, Inc., Chairman & Chief Executive Officer for Leucadia Technologies, Inc., Chairman & Chief Executive Officer at Gen-Probe, Inc., Chairman & Chief Executive Officer at Iris Molecular Diagnostics, Inc., President at IRIS Personalized Medicine, Inc., Director-Research & Development at Baxter Laboratories, Inc., Director & Chief Technology Officer at Iris International, Inc. and Chief Technology Officer at Hybritech, Inc. Thomas H. Adams received a doctorate from the University of California, Riverside. |
| Gary S. Jacob | Gary S. Jacob is a businessperson who has been at the helm of 7 different companies and currently holds the position of Chairman of ContraVir Pharmaceuticals, Inc., Chief Executive Officer & Director at Immuron Ltd. and President & Chief Executive Officer of Synergy Pharmaceuticals LLC. Dr. Jacob is also on the board of TrovaGene, Inc. In the past Dr. Jacob held the position of Chairman for Synergy Pharmaceuticals, Inc., Chairman of Synergy DE, President, Chief Executive & Scientific Officer at Callisto Pharmaceuticals, Inc., President, Chief Executive Officer & Director at Pawfect Foods, Inc., Glycobiology Director at G.D. Searle & Co. Ltd., Director-Functional Genomics at Monsanto Co. and Manager-Searle Glycobiology Group at the University of Oxford. Gary S. Jacob received a doctorate from the University of Wisconsin and an undergraduate degree from the University of Missouri. |
| Rodney S. Markin | Dr. Karsten Schmidt is Chief Technology Officer at TrovaGene, Inc. and Head-Administration at Zentrum f�0�1�0�4r Foren in der Grafischen Datenverarbeitung eV. Dr. Schmidt was previously employed as Vice President-Business Development by Sequenom, Inc. He received his doctorate degree from the University of Bonn. |
| Mark Erlander | Presently, Mark Erlander is Chief Scientific Officer at TrovaGene, Inc. In his past career he was Chief Scientific Officer at Biotheranostics, Inc., Chief Scientific Officer of Arcturus, Inc., Chief Scientific Officer at Gensignia Life Sciences, Inc., Principal at Johnson & Johnson and Assistant Professor at The Scripps Research Institute. He received a doctorate from the University of California, Los Angeles, a graduate degree from Iowa State University and an undergraduate degree from the University of California, Davis. |
| Paul R. Billings | Dr. Paul R. Billings is a Chief Medical Officer & Senior VP-Medical Affairs at Natera, Inc., an Independent Director at MetaStat, Inc., an Independent Director at TrovaGene, Inc., a Director & Chief Medical Officer at Fabric Genomics, Inc., an Executive Chairman at Melanoma Diagnostics, Inc., an Executive Chairman at Signature Genomics Laboratories LLC and a Professor at University of California, Berkeley. He is on the Board of Directors at MetaStat, Inc., TrovaGene, Inc., Applied Immunology, Inc., Aueon, Inc., Cynvenio Biosystems, Inc., DecisionQ Corp., Mission Bio, Inc., OmniSeq, Inc., PAX Neuoscience, Inc. and Fabric Genomics, Inc. Dr. Billings was previously employed as an Independent Director by Rennova Health, Inc., a Medical Director-IMPACT Program by Thermo Fisher Scientific, Inc., an Independent Director by Ancestry.com, Inc., a Chief Medical Officer by Life Technologies Corp., a President & Executive Officer by Cellective Dx Corp., a Co-Founder by CBR Systems, Inc., a Chairman by Biological Dynamics, Inc., a Co-Founder by GeneSage, Inc., a SVP-Corporate Development & Strategy by Laboratory Corp. of America Holdings, and a Vice President-Life Sciences & Clinical Affairs by Wipro Ltd. He also served on the board at CollabRx, Inc., Cyntellect, Inc., Celldex Therapeutics, Inc., Lipomics Technologies, Inc., PAX Scientific, Inc., BioScale, Inc. and SGL Carbon LLC. He received his undergraduate degree from the University of California, a doctorate degree from Harvard University and a doctorate degree from Harvard Medical School. |
| Rodney S. Markin | Rodney S. Markin founded LAB-InterLink. Currently, Dr. Markin is Chairman of PerceptiMed, Inc. He is also Chief Operating Officer at the University of Nebraska and on the board of 6 other companies. Dr. Markin previously held the position of Chairman, President & Chief Executive Officer at UNMC Physicians, Chairman for Transgenomic, Inc., Chief Executive Officer at LAB-InterLink and Chief Technology Officer at the University of Nebraska Medical Center. He received an undergraduate degree from Nebraska Wesleyan University, a doctorate from the University of Nebraska Medical Center and a doctorate from The University of Nebraska-Lincoln. |
| Rodney S. Markin | Rodney S. Markin founded LAB-InterLink. Currently, Dr. Markin is Chairman of PerceptiMed, Inc. He is also Chief Operating Officer at the University of Nebraska and on the board of 6 other companies. Dr. Markin previously held the position of Chairman, President & Chief Executive Officer at UNMC Physicians, Chairman for Transgenomic, Inc., Chief Executive Officer at LAB-InterLink and Chief Technology Officer at the University of Nebraska Medical Center. He received an undergraduate degree from Nebraska Wesleyan University, a doctorate from the University of Nebraska Medical Center and a doctorate from The University of Nebraska-Lincoln. |
| Stanley Neal Tennant | Stanley Neal Tennant occupies the position of President at Five Star Management, Inc. He is also on the board of Oak Ridge Financial Services, Inc., Bank of Oak Ridge (North Carolina) and TrovaGene, Inc. He received a doctorate from Wake Forest School of Medicine. |
| Athena Countouriotis | Athena Countouriotis is on the board of TrovaGene, Inc., Iovance Biotherapeutics, Inc. and NuMedii, Inc. and President, Chief Executive Officer & Director at Turning Point Therapeutics, Inc. She previously occupied the position of Chief Medical Officer & Senior Vice President at Adverum Biotechnologies, Inc., Chief Medical Officer & Senior Vice President of Halozyme Therapeutics, Inc., Director-Oncology Global Clinical Research at Bristol-Myers Squibb Co., Associate Medical Director at CTI BioPharma Corp. and Chief Medical Officer of Ambit Biosciences Corp. She received a doctorate from Tufts University School of Medicine and an undergraduate degree from the University of California, Los Angeles. |
| Rodney S. Markin | Dr. Karsten Schmidt is Chief Technology Officer at TrovaGene, Inc. and Head-Administration at Zentrum f�0�1�0�4r Foren in der Grafischen Datenverarbeitung eV. Dr. Schmidt was previously employed as Vice President-Business Development by Sequenom, Inc. He received his doctorate degree from the University of Bonn. |
| Rodney S. Markin | Dr. Karsten Schmidt is Chief Technology Officer at TrovaGene, Inc. and Head-Administration at Zentrum f�0�1�0�4r Foren in der Grafischen Datenverarbeitung eV. Dr. Schmidt was previously employed as Vice President-Business Development by Sequenom, Inc. He received his doctorate degree from the University of Bonn. |
| Athena Countouriotis | Athena Countouriotis is on the board of TrovaGene, Inc., Iovance Biotherapeutics, Inc. and NuMedii, Inc. and President, Chief Executive Officer & Director at Turning Point Therapeutics, Inc. She previously occupied the position of Chief Medical Officer & Senior Vice President at Adverum Biotechnologies, Inc., Chief Medical Officer & Senior Vice President of Halozyme Therapeutics, Inc., Director-Oncology Global Clinical Research at Bristol-Myers Squibb Co., Associate Medical Director at CTI BioPharma Corp. and Chief Medical Officer of Ambit Biosciences Corp. She received a doctorate from Tufts University School of Medicine and an undergraduate degree from the University of California, Los Angeles. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论